What The Study Did:
Adults experiencing a migraine of moderate or severe severity took the drug ubrogepant or placebo and reported if after two hours they were free of pain and of their most bothersome migraine-associated symptom in this randomized clinical trial.
To access the embargoed study:
Visit our For The Media website at this link
https:/
/
media.
jamanetwork.
com/
Authors:
Richard B. Lipton, M.D., of the Albert Einstein College of Medicine in Bronx, New York, is the corresponding author.
(doi:10.1001/jama.2019.16711)
Editor’s Note:
The article includes conflict of interest and funding/support disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
###
Media advisory:
The full study is linked to this news release.
Embed this link to provide your readers free access to the full-text article
This link will be live at the embargo time
https:/
/
jamanetwork.
com/
journals/
jama/
fullarticle/
10.
1001/
jama.
2019.
16711?guestAccessKey=
ebc7732d-e666-466d-ada8-55e70734166b&utm_source=
For_The_Media&utm_medium=
referral&utm_campaign=
ftm_links&utm_content=
tfl&utm_term=
111919
This part of information is sourced from https://www.eurekalert.org/pub_releases/2019-11/jn-tom111519.php
JAMA Network Media Relations
mediarelations@jamanetwork.org
@JAMA_current